RxDoctor Payments Data

Roger Williams, MD

Urology · Dothan, ALNPI 1174543821

Payments from drug & device makers

What this record shows

Axonics, Inc. accounts for 67.3% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2023 at $5,951 and has fallen 92.1% since, to $469 in 2025.

$10,291in general payments, 2019–2025

Across 243 payments — averaging $42.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$7K
  • Sumitomo Pharma America, Inc.$972
  • Astellas Pharma US Inc$898
  • Urovant Sciences Inc$277
  • Endo Pharmaceuticals Inc.$270
  • Boston Scientific$130
  • plus $819 from 21 others

What the payments were for

  • Travel & lodging$5,28451%
  • Food & beverage$5,00649%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,291 in reported general payments places this provider in the 85th percentile of 179 urology providers in Alabama.

See all urology providers in Alabama

Medicare billing

Part B allowed, 2024
$399,942
Medicare patients
1,049
Services billed
8,640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron153$116,080
Potassium Citrate ErPotassium Citrate184$25,974
Tamsulosin Hcl1,223$20,517
GemtesaVibegron25$17,296
Finasteride846$11,558
Testosterone Cypionate203$9,810
NitrofurantoinNitrofurantoin Macrocrystal160$6,953
ErtapenemErtapenem Sodium13$6,554
Oxybutynin Chloride ErOxybutynin Chloride222$5,240
Tadalafil41$4,005
Testosterone18$3,748
Ciprofloxacin Hcl624$3,412
Bicalutamide101$3,354
Tolterodine Tartrate ErTolterodine Tartrate19$3,268
Silodosin55$3,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$898$116,080153 claims
Sumitomo Pharma America, Inc.Gemtesa$972$17,29625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 179 urology providers in Alabama.

Other urology in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →